Harry Rowland

CEO

Harry is an accomplished medical technology leader with a record of building cardiovascular device companies from clinical concept to commercial use. As Chief Executive Officer of VahatiCor, he leads the company's mission to advance interventional therapies for patients with coronary microvascular dysfunction.

Harry was previously co-founder, CEO, and President of Endotronix, where he led the team that created the Cordella™️ Heart Failure System. Under his leadership, Endotronix completed the PROACTIVE-HF trial, achieved FDA premarket approval, and was acquired by Edwards Lifesciences in 2024. Harry holds a Ph.D. in Mechanical Engineering from the Georgia Institute of Technology and a B.S. in Mechanical Engineering from the University of California, Santa Barbara.

Kevin Van Bladel

CHIEF Technology Officer

Kevin is a distinguished medical technology leader with an impressive career spanning over three decades. Currently, he serves as Chief Technology Officer at VahatiCor Inc., leveraging his strong skills in business analysis, research, project management, and R&D.

Kevin's career includes a 13-year tenure at BioVentrix, where he held the positions of Sr VP of Product & Therapeutic Development and VP of R&D. His expertise in engineering has been demonstrated in various roles at Apsara Medical, BaroSense Inc., Sanarus Medical, Reflow Inc., General Surgical Innovations, Menlo Care (Acquired by J&J), and Mentor Corporation. Kevin holds a B.S. in Physics from Caltech.

Mark Niggli

CHIEF COMMERCIAL OFFICER

Mark directs the commercialization of the A-FLUX Reducer System® for patients with symptomatic CMD. He executes a full-scope commercial strategy encompassing KOL engagement, the development of clear value messaging, and the oversight of field training and implementation. Mark also leads efforts to secure reimbursement and patient access, ensuring the pathway for widespread and lasting adoption.

Angela Mallery

VP of Regulatory and Quality Affairs

Angela collaborates with innovative medical device companies to develop and implement regional and global regulatory strategies. Her expertise includes crafting successful Breakthrough Device and Safer Technologies Program (STeP) submissions, with a particular passion for pre-submissions and fostering interactive relationships with the FDA.

Janie Mandrusov

VP, Clinical Affairs

With a results-driven approach and a positive attitude, Janie consistently delivers impactful solutions that advance medical innovation and patient care.

She earned her BS in Biomedical Engineering from UC San Diego and her PhD in Chemical Engineering from Columbia University.

Jim Gaydon

PRINCIPAL ENGINEER

Jim delivers engineering design and documentation at VahatiCor, ensuring clear specifications and reliable hardware. His background includes roles at Boston Scientific, Shockwave Medical, and Guided Delivery Systems.

Marwan Berrada

FOUNDER AND CHAIRMAN

Marwan is an accomplished medical technology leader with a stellar record of leading and developing medical device businesses for over 20 years. In addition to serving as Founder and Chairman of VahatiCor, Marwan currently serves as the President, CEO, and Co-Founder of Advanced NanoTherapies, Inc. and T45 Labs.

An inventor at heart, Marwan works closely with R&D teams and has been a part of several first-generation medical device product launches. He is genuinely passionate about empowering the people around him and driving global medical innovation. Marwan holds a B.S. in Mechanical Engineering from the University of Minnesota and an MBA in Finance from McGill University.